Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Haemonetics Corp.

http://www.haemonetics.com

Latest From Haemonetics Corp.

'There Is Work To Do:' Sean Salmon Discusses Medtronic's Recent Hard-Won Cardio Breakthroughs

Medtech Insight caught up with Sean Salmon, the president of Medtronic's cardiovascular business, to talk about the long-awaited FDA approval of the Simplicity Spyral renal denervation system, recent approvals of the PulseSelect pulsed field ablation system and extravascular ICD, and the company's plans for transcatheter aortic valve replacement.

Exec Chats Cardiology

Updated: J&J Moves Closer To PFA Approval; New Data Presented At Boston AF

The AF Symposium in Boston Featured presentations of two trials of Johnson & Johnson/Biosense Webster’s Varipulse pulsed field ablation system and more safety data from the ADVENT trial of Boston Scientific’s Farapulse PFA.

Clinical Trials Cardiovascular

Boston Scientific Prepares For PFA Race In US And Asia

The FDA approved Boston Scientific’s Farapulse pulsed field ablation system, as expected, at the end of January, and the company believes regulators in China and Japan will approve it later this year. Brad Sutton, Boston Scientific’s chief medical officer for atrial fibrillation solutions, told Medtech Insight why PFA will soon dominate the atrial fibrillation ablation market and how his company plans to be a leader in PFA.

Clinical Trials Approvals

Cardio Catch-Up: Trial Of Abbott’s Volt PFA Begins; IDE Study To Start This Year

Abbott is behind rivals Boston Scientific and Medtronic in the race to capture share of the emerging pulsed field ablation market. PFA is set to eventually become the most common cardiac ablation modality because it is safer than radiofrequency or cryoablation.

Commercial Cardiology
See All

Company Information

UsernamePublicRestriction

Register